These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23584145)

  • 1. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
    Müller PJ; Rigbolt KT; Paterok D; Piehler J; Vanselow J; Lasonder E; Andersen JS; Schaper F; Sobota RM
    J Proteomics; 2013 Jun; 84():132-47. PubMed ID: 23584145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
    Fragale A; Tartaglia M; Wu J; Gelb BD
    Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome.
    Martinelli S; Nardozza AP; Delle Vigne S; Sabetta G; Torreri P; Bocchinfuso G; Flex E; Venanzi S; Palleschi A; Gelb BD; Cesareni G; Stella L; Castagnoli L; Tartaglia M
    J Biol Chem; 2012 Aug; 287(32):27066-77. PubMed ID: 22711529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
    Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
    Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes.
    Martinelli S; Torreri P; Tinti M; Stella L; Bocchinfuso G; Flex E; Grottesi A; Ceccarini M; Palleschi A; Cesareni G; Castagnoli L; Petrucci TC; Gelb BD; Tartaglia M
    Hum Mol Genet; 2008 Jul; 17(13):2018-29. PubMed ID: 18372317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
    Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
    Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pathogenic T42A mutation in SHP2 rewires the interaction specificity of its N-terminal regulatory domain.
    van Vlimmeren AE; Voleti R; Chartier CA; Jiang Z; Karandur D; Humphries PA; Lo WL; Shah NH
    Proc Natl Acad Sci U S A; 2024 Jul; 121(30):e2407159121. PubMed ID: 39012820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Noonan syndrome-associated D61G variant of the protein tyrosine phosphatase SHP2 prevents synaptic down-scaling.
    Lu W; Ai H; Xue F; Luan Y; Zhang B
    J Biol Chem; 2020 Jul; 295(29):10023-10031. PubMed ID: 32499374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13.
    Maheshwari M; Belmont J; Fernbach S; Ho T; Molinari L; Yakub I; Yu F; Combes A; Towbin J; Craigen WJ; Gibbs R
    Hum Mutat; 2002 Oct; 20(4):298-304. PubMed ID: 12325025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SHP2 sails from physiology to pathology.
    Tajan M; de Rocca Serra A; Valet P; Edouard T; Yart A
    Eur J Med Genet; 2015 Oct; 58(10):509-25. PubMed ID: 26341048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural, Functional, and Clinical Characterization of a Novel PTPN11 Mutation Cluster Underlying Noonan Syndrome.
    Pannone L; Bocchinfuso G; Flex E; Rossi C; Baldassarre G; Lissewski C; Pantaleoni F; Consoli F; Lepri F; Magliozzi M; Anselmi M; Delle Vigne S; Sorge G; Karaer K; Cuturilo G; Sartorio A; Tinschert S; Accadia M; Digilio MC; Zampino G; De Luca A; Cavé H; Zenker M; Gelb BD; Dallapiccola B; Stella L; Ferrero GB; Martinelli S; Tartaglia M
    Hum Mutat; 2017 Apr; 38(4):451-459. PubMed ID: 28074573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unveiling the Molecular Basis of the Noonan Syndrome-Causing Mutation T42A of SHP2.
    Toto A; Malagrinò F; Visconti L; Troilo F; Gianni S
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.
    Yu ZH; Zhang RY; Walls CD; Chen L; Zhang S; Wu L; Liu S; Zhang ZY
    Biochemistry; 2014 Jul; 53(25):4136-51. PubMed ID: 24935154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11).
    Qiu W; Wang X; Romanov V; Hutchinson A; Lin A; Ruzanov M; Battaile KP; Pai EF; Neel BG; Chirgadze NY
    BMC Struct Biol; 2014 Mar; 14():10. PubMed ID: 24628801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
    Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
    Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compound heterozygosity for PTPN11 variants in a subject with Noonan syndrome provides insights into the mechanism of SHP2-related disorders.
    Lorca R; Pannone L; Cuesta-Llavona E; Bocchinfuso G; Rodríguez-Reguero J; Carpentieri G; Hernando I; Flex E; Tartaglia M; Coto E; Gómez J; Martinelli S
    Clin Genet; 2021 Mar; 99(3):457-461. PubMed ID: 33354767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis.
    Stewart RA; Sanda T; Widlund HR; Zhu S; Swanson KD; Hurley AD; Bentires-Alj M; Fisher DE; Kontaridis MI; Look AT; Neel BG
    Dev Cell; 2010 May; 18(5):750-62. PubMed ID: 20493809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes.
    Keilhack H; David FS; McGregor M; Cantley LC; Neel BG
    J Biol Chem; 2005 Sep; 280(35):30984-93. PubMed ID: 15987685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.
    Anselmi M; Calligari P; Hub JS; Tartaglia M; Bocchinfuso G; Stella L
    J Chem Inf Model; 2020 Jun; 60(6):3157-3171. PubMed ID: 32395997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.
    Niihori T; Aoki Y; Ohashi H; Kurosawa K; Kondoh T; Ishikiriyama S; Kawame H; Kamasaki H; Yamanaka T; Takada F; Nishio K; Sakurai M; Tamai H; Nagashima T; Suzuki Y; Kure S; Fujii K; Imaizumi M; Matsubara Y
    J Hum Genet; 2005; 50(4):192-202. PubMed ID: 15834506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.